The Impact of Pravastatin Pretreatment on Periprocedural Microcirculatory Damage After Percutaneous Coronary Intervention

The Impact of Pravastatin Pretreatment on Periprocedural Microcirculatory Damage After Percutaneous Coronary Intervention - The Impact of Pravastatin Pretreatment on Periprocedural Microcirculatory Damage After Percutaneous Coronary Intervention

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002885

Enrollment

Registered

2009-12-13

Start date

2008-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angina Pectoris

Interventions

Drug: Pravastatin 20mg/day Control

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with stable angina who will undergo PCI. Plasma LDL cholesterol levels : >=100mg/dL and &#8804;160mg/dL Atherosclerotic lesion of >75% stenosis No history of statin administration

Exclusion criteria

Exclusion criteria: Patients with an atherosclerotic lesion with >50% stenosis at a left main trunk Contraindication of statin treatment

Design outcomes

Primary

Measure	Time frame
index of microcirculatory resistance by intracoronary pressure/temperature sensor-tipped guide wire	—

Secondary

Measure	Time frame
CK-MB, Troponin I at 8 and 24 hours after PCI	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026